MIT study links caspase-1 inhibition to reduced lung tumor incidence in mouse models

The study, published in Science Advances, used activity-based nanosensors to screen proteases in inflamed lung tissue from mice exposed to carcinogens that mimic smoking. Caspase-1 emerged as the dominant enzyme driving IL-1 beta maturation; daily oral dosing of the inhibitor VX-765 lowered tumor incidence from 78 percent in controls to 32 percent, with corresponding drops in inflammatory cytokine levels measured by multiplex ELISA.

This finding extends the 2017 CANTOS trial, in which canakinumab reduced lung cancer incidence by 67 percent in patients with elevated CRP, yet showed no benefit once tumors were established. The mouse data suggest the window for intervention is pre-malignant inflammation rather than overt malignancy, aligning with Swanton lab proteomic signatures that predict IL-1 beta responsiveness.

Remaining questions include whether chronic caspase-1 blockade alters microbiome or wound-healing responses in humans and whether efficacy holds in never-smoker models driven by EGFR or ALK alterations. Next steps require a window-of-opportunity trial measuring premalignant lesion regression via autofluorescence bronchoscopy in high-risk former smokers.